Author:
Noll E.,Burgin M.,Thibaud A.,Vogel T.,Pottecher J.,Diemunsch P.
Publisher
Springer Science and Business Media LLC
Subject
Geriatrics and Gerontology
Reference35 articles.
1. Gegu M, Chevalet P, Piloquet FX, et al (2013) General characteristics of the new oral anticoagulants. Geriatr Psychol Neuropsychiatr Vieil 11:4–9
2. Ma TKW, Yan BP, Lam YY (2011) Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data. Pharmacol Ther 129:185–94
3. Rocket AF (2010) Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the Rocket AF study. Am Heart J 159:340–7
4. Kubitza D, Becka M, Roth A, Mueck W (2013) The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban: an oral, direct factor Xa inhibitor. J Clin Pharmacol 53:249–55
5. Pouyanne P, Haramburu F, Imbs JL, Bégaud B (2000) Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ 320:1036